You need to enable JavaScript to run this app.
Recon: Novo Nordisk pays $2.4B to build French plant for GLP-1 drugs production; UK names synthetic opioids to its banned drugs list
Recon
Jason Scott
Global
ReconJason Scott
GlobalReconJason ScottGlobal